Genmab A (GMAB) Receivables (2023 - 2025)

Genmab A (GMAB) has disclosed Receivables for 3 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 949.12% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, up 949.12%, and an annual FY2025 reading of $1.2 billion, up 949.12% over the prior year.
  • Receivables was $1.2 billion for Q4 2025 at Genmab A, up from $114.0 million in the prior quarter.
  • Across five years, Receivables topped out at $1.2 billion in Q4 2025 and bottomed at $114.0 million in Q4 2024.
  • Average Receivables over 3 years is $698.7 million, with a median of $786.0 million recorded in 2023.
  • The sharpest move saw Receivables tumbled 85.5% in 2024, then skyrocketed 949.12% in 2025.
  • Year by year, Receivables stood at $786.0 million in 2023, then crashed by 85.5% to $114.0 million in 2024, then surged by 949.12% to $1.2 billion in 2025.
  • Business Quant data shows Receivables for GMAB at $1.2 billion in Q4 2025, $114.0 million in Q4 2024, and $786.0 million in Q4 2023.